Amalgamated Bank grew its position in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 78.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,994 shares of the medical research company’s stock after buying an additional 12,295 shares during the quarter. Amalgamated Bank’s holdings in EXACT Sciences were worth $1,674,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently bought and sold shares of EXAS. Quantbot Technologies LP bought a new stake in shares of EXACT Sciences in the 1st quarter worth approximately $135,000. Bronfman E.L. Rothschild L.P. grew its stake in EXACT Sciences by 160.8% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,464 shares of the medical research company’s stock valued at $140,000 after buying an additional 2,136 shares in the last quarter. Sandy Spring Bank grew its stake in EXACT Sciences by 50.2% in the 1st quarter. Sandy Spring Bank now owns 4,672 shares of the medical research company’s stock valued at $188,000 after buying an additional 1,562 shares in the last quarter. NJ State Employees Deferred Compensation Plan purchased a new position in EXACT Sciences in the 1st quarter valued at approximately $202,000. Finally, Private Advisor Group LLC purchased a new position in EXACT Sciences in the 1st quarter valued at approximately $227,000. 88.20% of the stock is currently owned by hedge funds and other institutional investors.
EXAS has been the subject of a number of recent research reports. BTIG Research lifted their price objective on shares of EXACT Sciences from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, May 30th. BidaskClub upgraded shares of EXACT Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 7th. Leerink Swann reiterated an “outperform” rating and issued a $76.00 price objective (up from $67.00) on shares of EXACT Sciences in a research note on Wednesday, July 18th. Jefferies Financial Group reduced their price objective on shares of EXACT Sciences from $60.00 to $57.00 and set a “buy” rating for the company in a research note on Thursday, August 2nd. Finally, Canaccord Genuity boosted their price target on shares of EXACT Sciences from $68.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, June 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $65.45.
EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, August 1st. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.03. The business had revenue of $102.89 million during the quarter, compared to the consensus estimate of $104.40 million. EXACT Sciences had a negative net margin of 35.24% and a negative return on equity of 20.10%. The firm’s revenue for the quarter was up 78.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.27) earnings per share. research analysts anticipate that EXACT Sciences Co. will post -1.31 EPS for the current fiscal year.
In other news, Director Thomas D. Carey sold 3,427 shares of the company’s stock in a transaction dated Monday, July 30th. The shares were sold at an average price of $58.86, for a total transaction of $201,713.22. Following the completion of the transaction, the director now directly owns 48,983 shares of the company’s stock, valued at $2,883,139.38. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Jeffrey Thomas Elliott sold 8,984 shares of the company’s stock in a transaction dated Monday, July 30th. The shares were sold at an average price of $57.78, for a total transaction of $519,095.52. Following the transaction, the chief financial officer now directly owns 22,690 shares of the company’s stock, valued at $1,311,028.20. The disclosure for this sale can be found here. Insiders sold 14,546 shares of company stock valued at $846,987 over the last three months. 3.20% of the stock is currently owned by insiders.
EXACT Sciences Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Recommended Story: Diversification For Individual Investors
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.